In order to validate the JAG1 gene and its protein jagged1 as a therapeutic target, first we assessed the effect of stimulating human PBMCs from MS patients in vitro with a Jagged1 peptide agonist [33]. The gene discussed is JAG1; the disease is myeloid sarcoma.